Document is current

Article History

Received: 19 March 2019

Accepted: 9 July 2019

First Online: 7 August 2019

Ethics approval and consent to participate

: The trial was a large multicenter study and was approved by the relevant institutional review board for each site. Written informed consent was provided by the patient or his/her legal representative.

: Not applicable.

: MFE, YM, TV, JK, JS, CF, EM, CL, and DM are current or former employees of, and own/owned stock in, MSD.JLC has received in-kind research support from Avid Radiopharmaceuticals and Teva Pharmaceuticals and has served as a consultant to the following companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, BiOasis Technologies, Biogen, Boehinger-Ingelheim, Bracket, Casava, Eisai, GE Healthcare, Genentech, Grifols, Kyowa, Lundbeck, Medavante, MSD, Nutricia, Orion, Otsuka, Pfizer, QR Pharma, Resverlogix, Roche, Samus, Samumed, Suven, Takeda, Toyoma, United Neuroscience. He owns stock in ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, and Neurokos. He is the copyright holder on the Neuropsychiatric Inventory. He receives support from Keep Memory Alive and COBRE award P20GM109025.PNT has received consulting fees from Acadia, Abbott Laboratories, AbbVie, AC Immune, Auspex, Boehringer-Ingelheim, Chase Pharmaceuticals, Eisai, GliaCure, Insys Therapeutics, and Pfizer. He has received consulting fees and research support from AstraZeneca, Avanir, Eli Lilly, Lundbeck, MSD, Roche, and research support only Amgen, Avid, Biogen, Elan, Functional Neuromodulation (f (nm)), GE Healthcare, Genentech, Novartis, and Targacept. He has received other research support from the NIA and Arizona Department of Health Services and holds stock options in ADAMAS.PSA has served as a consultant to the following companies: NeuroPhage, Eli Lilly, MSD, Avanir, Roche, Novartis, Pfizer, AstraZeneca, Janssen, Lundbeck, Biogen, Probiodrug, Anavex, Abbvie, Janssen, Cytox, and aTyr. He receives research support from Eli Lilly, Janssen, the Alzheimer’s Association, and the NIH.BV has served as a consultant to the following companies: Transition Therapeutics, Takeda, Otsuka, Lilly, Nestlé, MSD, Biogen, and Roche. He receives research support from Abbvie, Lilly, MSD, Otsuka, Sanofi, Alzheon, Astra-Zénéca, LPG Systems Nestlé, The Alzheimer’s Association, The Alzheimer Drug Discovery Foundation, The European Commission, and French Ministry of Health.